Alpha-2 Agonist Retinal Compositions for Neuroprotection and Vision

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current treatments for retinal diseases such as age-related macular degeneration, diabetic retinopathy, and glaucoma are inadequate in providing effective retinal neuroprotection and vision enhancement.

Innovation Solution

Pharmaceutical compositions containing medetomidine, dexmedetomidine, or OH-dexmedetomidine, which act as alpha-2 adrenergic agonists, are administered to treat retinal diseases and enhance vision by activating all three alpha-2 receptor subtypes, reducing receptor desensitization, and providing sustained therapeutic effects through various delivery methods.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If current treatments for retinal diseases are used, then some therapeutic effect is achieved, but effective retinal neuroprotection and vision enhancement are not provided

Engineering Contradiction:

Improveretinal neuroprotection efficacyVSAvoidvision enhancement effectiveness

Core Design Contradiction:

ReliabilityVSProductivity

Solution Approach 1:

The patent changes the pharmacological parameters by using dexmedetomidine and its metabolite OH-dexmedetomidine as alpha-2 adrenergic agonists, which have different receptor binding characteristics compared to conventional treatments. This parameter change enables simultaneous activation of all three alpha-2 receptor subtypes, providing both neuroprotection and vision enhancement effects that were not achievable with previous treatments.

Inventive Principle:

Principle #35Parameter changes

Solution Approach 2:

The patent combines multiple therapeutic mechanisms into a single composition by utilizing both dexmedetomidine and its active metabolite OH-dexmedetomidine together with pharmaceutically acceptable carriers. This composite approach allows the formulation to provide multiple benefits (neuroprotection, reduced receptor desensitization, sustained activity) simultaneously, resolving the contradiction between reliability and productivity.

Inventive Principle:

Principle #40Composite materials

2Stability of the object's composition

If dexmedetomidine is used as a partial agonist of alpha2A receptor, then receptor desensitization is reduced, but sustained activity is compromised

Engineering Contradiction:

Improvereceptor desensitizationVSAvoidsustained activity

Core Design Contradiction:

Stability of the object's compositionVSDuration of action of moving object

Solution Approach 1:

The patent ensures continuous therapeutic action by utilizing both dexmedetomidine and its active metabolite OH-dexmedetomidine, which has a longer half-life. The metabolite continues to activate alpha-2 adrenergic receptors after the parent compound is metabolized, maintaining sustained activity while preserving the benefit of reduced receptor desensitization through partial agonism at the alpha2A subtype.

Inventive Principle:

Principle #20Continuity of useful action

Solution Approach 2:

The patent effectively 'recovers' and utilizes the active metabolite OH-dexmedetomidine that would otherwise be discarded as a waste product. This metabolite continues to provide therapeutic activity, extending the duration of action and ensuring sustained alpha-2 adrenergic receptor activation without requiring continuous administration of the parent compound.

Inventive Principle:

Principle #34Discarding and recovering

3Reliability

If multiple delivery methods are used for pharmaceutical compositions, then therapeutic effectiveness is improved, but formulation complexity increases

Engineering Contradiction:

Improvetherapeutic effectivenessVSAvoidformulation complexity

Core Design Contradiction:

ReliabilityVSDevice complexity

Solution Approach 1:

The patent creates a universal pharmaceutical composition that can be administered through multiple delivery methods (topical ocular application, direct injection, slow-release formulations) while maintaining the same core therapeutic mechanism. This multi-functional formulation approach allows the same active ingredients (dexmedetomidine and OH-dexmedetomidine) to be delivered via different routes, improving therapeutic effectiveness without proportionally increasing formulation complexity.

Inventive Principle:

Principle #6Universality (Multi-functionality)

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The compositions effectively reduce retinal damage and enhance vision by improving contrast sensitivity, night vision, and acuity without causing cell loss, using methods like topical application, direct injection, and slow-release formulations.

Implementation Method 1

Dexmedetomidine is a potent alpha2-adrenergic agonist, activating all three alpha2 receptor subtypes... Pharmacological activation of the alpha 2 adrenergic receptor by brimonidine is a well established treatment for various visual disorders of the eye

Methodology Applied

Scientific EffectAlpha-2 adrenergic receptor activation:

Data Source

PatentUS20250375423A1Pharmaceutical compositions comprising 4-[1-(2,3-dimethylphenyl)ethyl]-3h-imidazole derivatives for treating retinal diseases

Publication Date: 2025.12.11 ALLERGAN INC

AI summary

The present invention relates to pharmaceutical compositions, containing 4-[1-(2,3-dimethylphenyl)ethyl]-1H-imidazole, (S) 4-[1-(2,3-dimethylphenyl)ethyl]-1H-imidazole or (S) [3-(1-(1H-imidazol-4-yl)ethyl)-2-methylphenyl]methanol, their use as pharmaceuticals for the treatment of retinal diseases, for retinal neuroprotection and vision enhancement.